| 88501-2 |
OASIS D - Medications - start of care or resumption of care |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
OASIS D - Medications - start of care or resumption of care during assessment period [CMS Assessment] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
88501-2 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Dextro; Outcome and assessment information set; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Started; Survey |
2.77 |
2.64 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; Release 2.72: LONG_COMMON_NAME: Updated to improve clarity; |
0 |
| 88502-0 |
OASIS E - Preferences for Customary Routine Activities - DC |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
OASIS E - Preferences for Customary Routine Activities - DC during assessment period [CMS Assessment] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
88502-0 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Outcome and assessment information set; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.77 |
2.64 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; Release 2.72: COMPONENT: updated form; |
0 |
| 88503-8 |
OASIS D - Therapy need and plan of care |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
OASIS D - Therapy need and plan of care during assessment period [CMS Assessment] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
88503-8 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Dextro; Outcome and assessment information set; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.77 |
2.64 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; |
0 |
| 88504-6 |
OASIS D - Data items collected at inpatient facility admission or agency discharge only - transfer |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
OASIS D - Data items collected at inpatient facility admission or agency discharge only - transfer during assessment period [CMS Assessment] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
88504-6 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Dextro; Disch; Outcome and assessment information set; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.77 |
2.64 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; |
0 |
| 88505-3 |
OASIS D - Data items collected at inpatient facility admission or agency discharge only - discharge from agency - death at home |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
OASIS D - Data items collected at inpatient facility admission or agency discharge only - discharge from agency - death at home during assessment period [CMS Assessment] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
88505-3 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Dextro; Disch; Inpatient admission agency discharge items - d/c from agency; Outcome and assessment information set; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.77 |
2.64 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; |
0 |
| 88506-1 |
OASIS D - Data items collected at inpatient facility admission or agency discharge only - discharge from agency |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
OASIS D - Data items collected at inpatient facility admission or agency discharge only - discharge from agency during assessment period [CMS Assessment] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
88506-1 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Dextro; Disch; Inpatient admission agency discharge items - d/c from agency; Outcome and assessment information set; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.77 |
2.64 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; |
0 |
| 88507-9 |
OASIS D - Sensory status - discharge from agency |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
OASIS D - Sensory status - discharge from agency during assessment period [CMS Assessment] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
88507-9 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Dextro; Disch; Outcome and assessment information set; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.77 |
2.64 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; |
0 |
| 88508-7 |
OASIS D - Current number of unhealed pressure injuries at each stage - discharge from agency |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
OASIS D - Current number of unhealed pressure injuries at each stage - discharge from agency during assessment period [CMS Assessment] |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
88508-7 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Dextro; Disch; No; Num; Outcome and assessment information set; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Pressure ulcer; Pressure Ulcers; Report period; Survey |
2.8 |
2.64 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; Previous Releases: "Pressure ulcers" has been updated to "pressure injuries" according to the new guidelines by the NPUAP and as approved by the Clinical LOINC. |
0 |
| 88509-5 |
Helicobacter pylori 23S rRNA clarithromycin resistance mutation |
Prid |
Isolate/Specimen |
Pt |
Nom |
Molgen |
|
ACTIVE |
Helicobacter pylori 23S rRNA clarithromycin resistance mutation [Identifier] by Molecular method |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
88509-5 |
|
Molgen |
|
|
Both |
|
|
|
0 |
H pylori 23S clarithro res mut Islt/Spm |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; Biaxin; C pylori; Campylobacter pylori; Claripen; H pyl; H pylori; H pylori 23S rRNA clarith res; ID; Identity or presence; Infectious Disease; InfectiousDisease; Islt; Islt/Spm; Isol; Klacid; Molecular genetics; Mut; Mutations; Nominal; PCR; Point in time; Random; Resist; Resistanc; Resistant; Resistent; ribosomal RNA; Spec |
2.65 |
2.64 |
|
|
|
|
|
|
|
|
|
|
Updated System from "Isolate" and Method from "Probe.amp.tar" according to the new, more sustainable model for LOINC molecular resistance terms [Approved by LOINC Laboratory Committee in June 2018]. |
0 |
| 8851-8 |
Oxygen saturation |
MFr |
Pulmonary artery.left |
Pt |
Qn |
|
|
ACTIVE |
Left pulmonary artery Oxygen saturation |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEMODYN.MOLEC |
|
8851-8 |
|
|
|
|
|
|
|
|
0 |
SaO2 % PA-L |
|
|
|
|
|
Art; Cardio; Cardiology; Heart Disease; Hemodynamics; HEMODYNAMICS.MOLEC; L; LT; Lung; Mass Fraction; O2; PA; PA-L; Percent; Point in time; Pulmonary; Pulmonology; QNT; Quan; Quant; Quantitative; Random; Respiratory; SaO2; SAT; Satn; SO2; tO2 |
2.54 |
1.0h(3) |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 88510-3 |
Natural killer cell cytotoxicity.30:1 effector to target cell ratio/Positive control |
RelACnc |
Bld MC |
Pt |
Qn |
|
|
ACTIVE |
Natural killer cell cytotoxicity.30:1 effector to target cell ratio/Positive control in Blood mononuclear cells |
|
ADD |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
88510-3 |
|
|
|
|
Observation |
|
|
|
0 |
NK cytotox.30:1 E:T/Pos cntrl Bld MC |
|
|
|
|
|
Blood; HEMATOLOGY/CELL COUNTS; i; NK; NK cytotox.30:1 E:T; NK cytotoxicity; PBMC; Peripheral blood mononuclear cells; Point in time; Pos; Pos cntrl; QNT; Quan; Quant; Quantitative; Random; RlACnc; WB; Whole blood |
2.64 |
2.64 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 88511-1 |
Natural killer cell cytotoxicity.0.9:1 effector to target cell ratio/Positive control |
RelACnc |
Bld MC |
Pt |
Qn |
|
|
ACTIVE |
Natural killer cell cytotoxicity.0.9:1 effector to target cell ratio/Positive control in Blood mononuclear cells |
|
ADD |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
88511-1 |
|
|
|
|
Observation |
|
|
|
0 |
NK cytotox.0.9:1 E:T/Pos cntrl Bld MC |
|
|
|
|
|
Blood; HEMATOLOGY/CELL COUNTS; i; NK; NK cytotox.0.9:1 E:T; PBMC; Peripheral blood mononuclear cells; Point in time; Pos; Pos cntrl; QNT; Quan; Quant; Quantitative; Random; RlACnc; WB; Whole blood |
2.64 |
2.64 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 88512-9 |
Natural killer cell cytotoxicity.15:1 effector to target cell ratio/Positive control |
RelACnc |
Bld MC |
Pt |
Qn |
|
|
ACTIVE |
Natural killer cell cytotoxicity.15:1 effector to target cell ratio/Positive control in Blood mononuclear cells |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
88512-9 |
|
|
|
|
Observation |
|
|
|
0 |
NK cytotox.15:1 E:T/Pos cntrl Bld MC |
|
|
|
|
|
Blood; HEMATOLOGY/CELL COUNTS; i; NK; NK cytotox.15:1 E:T; NK cytotoxicity; PBMC; Peripheral blood mononuclear cells; Point in time; Pos; Pos cntrl; QNT; Quan; Quant; Quantitative; Random; RlACnc; WB; Whole blood |
2.7 |
2.64 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 88513-7 |
Natural killer cell cytotoxicity.7.5:1 effector to target cell ratio/Positive control |
RelACnc |
Bld MC |
Pt |
Qn |
|
|
ACTIVE |
Natural killer cell cytotoxicity.7.5:1 effector to target cell ratio/Positive control in Blood mononuclear cells |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
88513-7 |
|
|
|
|
Observation |
|
|
|
0 |
NK cytotox.7.5:1 E:T/Pos cntrl Bld MC |
|
|
|
|
|
Blood; HEMATOLOGY/CELL COUNTS; i; NK; NK cytotox.7.5:1 E:T; PBMC; Peripheral blood mononuclear cells; Point in time; Pos; Pos cntrl; QNT; Quan; Quant; Quantitative; Random; RlACnc; WB; Whole blood |
2.7 |
2.64 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 88514-5 |
Natural killer cell cytotoxicity.1.88:1 effector to target cell ratio/Positive control |
RelACnc |
Bld MC |
Pt |
Qn |
|
|
ACTIVE |
Natural killer cell cytotoxicity.1.88:1 effector to target cell ratio/Positive control in Blood mononuclear cells |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
88514-5 |
|
|
|
|
Observation |
|
|
|
0 |
NK cytotox.1.88:1 E:T/Pos cntrl Bld MC |
|
|
|
|
|
Blood; HEMATOLOGY/CELL COUNTS; i; NK; NK cytotox.1.88:1 E:T; PBMC; Peripheral blood mononuclear cells; Point in time; Pos; Pos cntrl; QNT; Quan; Quant; Quantitative; Random; RlACnc; WB; Whole blood |
2.7 |
2.64 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 88515-2 |
Natural killer cell cytotoxicity.3.75:1 effector to target cell ratio/Positive control |
RelACnc |
Bld MC |
Pt |
Qn |
|
|
ACTIVE |
Natural killer cell cytotoxicity.3.75:1 effector to target cell ratio/Positive control in Blood mononuclear cells |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
88515-2 |
|
|
|
|
Observation |
|
|
|
0 |
NK cytotox.3.75:1 E:T/Pos cntrl Bld MC |
|
|
|
|
|
Blood; HEMATOLOGY/CELL COUNTS; i; NK; NK cytotox.3.75:1 E:T; PBMC; Peripheral blood mononuclear cells; Point in time; Pos; Pos cntrl; QNT; Quan; Quant; Quantitative; Random; RlACnc; WB; Whole blood |
2.7 |
2.64 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 88516-0 |
Gastrointestinal pathogens |
Prid |
XXX |
Pt |
Nom |
Probe.amp.tar |
|
ACTIVE |
Gastrointestinal pathogens identified in Specimen by NAA with probe detection |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
88516-0 |
|
Probe.amp.tar |
|
|
Observation |
|
|
|
0 |
GI pathogens Spec NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; Gastro; Gastroenterology; GI; GI pathogens; ID; Identity or presence; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nominal; Nucleic acid sequence based analysis; Other; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.79 |
2.64 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; |
0 |
| 88517-8 |
Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells^^corrected for background |
ACnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells [Units/volume] corrected for background in Blood |
|
MIN |
DefinitionDescription |
|
|
IU/mL |
|
|
|
|
|
|
MICRO |
|
88517-8 |
|
|
|
|
Both |
|
|
|
0 |
M TB IFN-g CD4+CD8+ bckgrnd cor Bld-aCnc |
|
|
|
|
|
Acid Fast; Acid Fast Bacilli; Acid fast bacillus; AFB; Arbitrary concentration; bckgrd cor; Blood; Cell; Cellularity; Helper T cells; ID; IFN; IGRA; Inducer T cells; Infectious Disease; InfectiousDisease; L3T4; Leu2; Leu-2; Leu3; Leu-3; Lung; M tb; M TB IFN-g; M TBIFN-g CD4+ CD8+T-cells; M tuberculosis; Microbiology; Mtb; Myco; Mycobact; Mycobacterium tuberculosum; Point in time; Pulmonary; Pulmonology; QNT; Quan; Quant; Quantitative; Random; Respiratory; Suppressor T cells; T prime; T4; T-4; T8; T-8; TB; Tsuppressor; Tuberculosis; W3/25; WB; Whole blood |
2.73 |
2.64 |
|
|
|
|
|
|
|
[IU]/mL |
|
|
Changed Component from Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells^^corrected for background to Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells^^corrected for background to be consistant with LOINC cell marker naming conventions. |
0 |
| 88518-6 |
Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells |
ACnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells [Units/volume] in Blood |
|
ADD |
DefinitionDescription |
|
|
IU/mL |
|
|
|
|
|
|
MICRO |
|
88518-6 |
|
|
|
|
Both |
|
|
|
0 |
M TBIFN-g CD4+ CD8+T-cells Bld-aCnc |
|
|
|
|
|
Acid Fast; Acid Fast Bacilli; Acid fast bacillus; AFB; Arbitrary concentration; Blood; Cell; Cellularity; Helper T cells; ID; IFN; IGRA; Inducer T cells; Infectious Disease; InfectiousDisease; L3T4; Leu2; Leu-2; Leu3; Leu-3; Lung; M tb; M TB IFN-g; M TBIFN-g CD4+ CD8+T-cells; M tuberculosis; Microbiology; Mtb; Myco; Mycobact; Mycobacterium tuberculosum; Point in time; Pulmonary; Pulmonology; QNT; Quan; Quant; Quantitative; Random; Respiratory; Suppressor T cells; T prime; T4; T-4; T8; T-8; TB; Tsuppressor; Tuberculosis; W3/25; WB; Whole blood |
2.64 |
2.64 |
|
|
|
|
|
|
|
[IU]/mL |
|
|
Changed Component from Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells to Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells to be consistant with LOINC cell marker naming conventions. |
0 |
| 88519-4 |
KIT gene.c.2447A>T |
PrThr |
Bld/Tiss |
Pt |
Ord |
Molgen |
|
ACTIVE |
KIT gene c.2447A>T [Presence] in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
88519-4 |
|
Molgen |
|
|
Both |
|
|
|
0 |
KIT c.2447A>T Bld/T Ql |
|
|
|
|
|
Acute myeloid leukemia; Blood; CD117; C-Kit; D816V; Gastrointestinal Stromal Tumor; Genetics; Germ Cell Tumors; GIST; Heredity; Heritable; Inherited; KIT c.2447A>T; mast/stem cell growth factor receptor; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Ordinal; PBT; PCR; piebald trait; Point in time; PR; Proto-oncogene tyrosine-protein kinase Kit; QL; Qual; Qualitative; Random; SCFR; Screen; soluble KIT variant; Systemic Mastocytosis; T prime; Tissue; Tissue, unspecified; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; WB; Whole blood; Whole blood or Tissue |
2.73 |
2.64 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 8852-6 |
Oxygen saturation |
MFr |
Pulmonary artery.main |
Pt |
Qn |
|
|
ACTIVE |
Main pulmonary artery Oxygen saturation |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEMODYN.MOLEC |
|
8852-6 |
|
|
|
|
|
|
|
|
0 |
SaO2 % MPA |
|
|
|
|
|
Art; Cardio; Cardiology; Heart Disease; Hemodynamics; HEMODYNAMICS.MOLEC; Lung; Mass Fraction; MPA; O2; PA; Percent; Point in time; Pulmonary; Pulmonology; QNT; Quan; Quant; Quantitative; Random; Respiratory; SaO2; SAT; Satn; SO2; tO2 |
2.4 |
1.0h(3) |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 88520-2 |
OASIS D - Medications - discharge from agency |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
OASIS D - Medications - discharge from agency during assessment period [CMS Assessment] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
88520-2 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Dextro; Disch; Outcome and assessment information set; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.77 |
2.64 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; |
0 |
| 88521-0 |
IRF-PAI v2.0 - Staff assessment for mental status |
- |
^Patient |
3D |
- |
CMS Assessment |
|
ACTIVE |
IRF-PAI v2.0 - Staff assessment for mental status [CMS Assessment] |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
88521-0 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
3 days; Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Survey |
2.69 |
2.64 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.69: COMPONENT: Updated to reflect the most recent version that uses this panel.; TIME_ASPCT: Corrected to align with the Timing for the child term in this panel.; Release 2.67: COMPONENT: Updated to reflect most recent version; Previous Releases: This panel is in versions 2.0 and 3.0, so "v3.0" was added to the Component. |
0 |
| 88522-8 |
IRF-PAI v2.0 - Hearing, speech, and vision - admission |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
IRF-PAI v2.0 - Hearing, speech, and vision - admission during assessment period [CMS Assessment] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
88522-8 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.77 |
2.64 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; Release 2.69: COMPONENT: Updated to state the most recent version of IRF-PAI that uses this panel.; Previous Releases: This panel is in versions 2.0 and 3.0, so "v3.0" was added to the Component. |
0 |
| 88523-6 |
IRF-PAI v2.0 - Quality indicators - admission |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
IRF-PAI v2.0 - Quality indicators - admission during assessment period [CMS Assessment] |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
88523-6 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.77 |
2.64 |
|
Organizer |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; Release 2.69: COMPONENT: Updated to only include IRF-PAI v2.0 in the name since active and future versions have been updated with the new reporting period terms and therefore have different children.; Previous Releases: This panel is in versions 2.0 and 3.0, so "v3.0" was added to the Component. |
0 |
